Molecular ablation of ventricular tachycardia after myocardial infarction
- 29 October 2006
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 12 (11) , 1256-1258
- https://doi.org/10.1038/nm1503
Abstract
Ventricular tachycardia is a common and lethal complication after myocardial infarction. Here we show that focal transfer of a gene encoding a dominant-negative version of the KCNH2 potassium channel (KCNH2-G628S) to the infarct scar border eliminated all ventricular arrhythmias in a porcine model. No proarrhythmia or other negative effects were discernable. Our results demonstrate the potential viability of gene therapy for ablation of ventricular arrhythmias.Keywords
This publication has 12 references indexed in Scilit:
- Complications Associated With Implantable Cardioverter-Defibrillator Replacement in Response to Device AdvisoriesJAMA, 2006
- In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotypeAmerican Journal of Physiology-Heart and Circulatory Physiology, 2003
- Expression and Function of a Biological Pacemaker in Canine HeartCirculation, 2003
- Biological pacemaker created by gene transferNature, 2002
- Focal modification of electrical conduction in the heart by viral gene transferNature Medicine, 2000
- Radiofrequency Catheter Ablation of Postinfarction Ventricular TachycardiaCirculation, 1997
- Sustained expression of genes delivered directly into liver and muscle by lentiviral vectorsNature Genetics, 1997
- Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectorsNature Genetics, 1997
- Avoidance of Immune Response Prolongs Expression of Genes Delivered to the Adult Rat Myocardium by Replication-Defective AdenovirusCirculation, 1996
- Cellular uncoupling can unmask dispersion of action potential duration in ventricular myocardium. A computer modeling study.Circulation Research, 1989